Dalya Soond Rosner
Redwood City,USA
Summary
Accomplished immunologist with 15 years of expertise in immuno-oncology, inflammation, and translational research. Experienced leader in cross-functional team management, target discovery, and preclinical development, with a proven track record of advancing programs through IND submission. Dedicated to accelerating oncology research through innovative strategies and collaborative efforts.
Overview
16
16
years of professional experience
Work History
Staff Scientist
Alector
01.2023 - Current
- Directed antibody-and protein-replacement neuro-immunology programs, achieving IND clearance and strategic milestones
- Designed in vitro and in vivo strategies for myeloid cell modulation, MOA exploration and combination therapy internally and externally with academic collaborators and CROs
- Partnered with leading KOLs to reverse translate adverse events seen in clinic to de-risk backup molecules
- Led and collaborated synergistically with cross-functional teams across multiple scientific, computational, regulatory and business departments to align program priorities
- Mentored junior scientists, fostering career growth and advancing team capabilities
Senior Scientist
True Binding
01.2020 - 01.2021
- Contributed experimentally and strategically to 2 IND submissions and filed 5 patents
- Drafted technical reports and designed follow-up studies for IP development for immuno-oncology, inflammation and neurologic targets
Scientist II
IGM Biosciences
01.2016 - 01.2020
- Pioneered mono- and bi-specific antibody approaches for T-cell activation and tumor-targeted cytokines in oncology
- Selected targets and developed tumor models and in vitro assays to validate therapeutic candidates
- Collaborated with external partners and CROs for translational research efforts
Postdoctoral Fellow
University of Birmingham
01.2012 - 01.2016
- Investigated T-cell and macrophage signaling mechanisms and their implications for inflammation, immunity and immunotherapy
Postdoctoral Fellow
University of Cambridge
01.2009 - 01.2012
- Investigated T-cell and macrophage signaling mechanisms and their implications for inflammation, immunity and immunotherapy
Education
Ph.D. - Immunology
University of Cambridge
M.Sc. - Immunology
University of Colorado
B.A. - Biology
University of Pennsylvania
Skills
- Cancer Immunology
- Tumor Microenvironment
- Mechanism of Action Studies
- Target Validation
- Cross-Functional Team Leadership
- Mentorship
- IND-Enabling Studies
- IND Submission
- Cell isolation
- Cell differentiation
- Cell culture
- Immunological assays
- T cell activation
- Cytokine production
- Target cell killing
- Suppression
- Immunophenotyping
- Myeloid cell phagocytosis
- Mast cell degranulation
- ADCC assays
- ADCP assays
- CDC assays
- Cell and molecular biology techniques
- FACS
- ELISA
- Cytokine measurements
- PCR
- Signal transduction
- Reporter assays
- Western blotting
- Immunoprecipitation
- Gene modification
- CRISPR
- Lenti-virus
- Adeno-virus
- Transfections
- Cell line generation
- Incucyte assays
- Lysosomal function
- Confocal microscopy
- RNASeq
- Proteomic interpretation
- In vivo models
- PK assay design
- Ex vivo immunophenotyping
- Tumor models
- Alzheimer’s models
- CIA
- CAIA
- Sterile sepsis
- Listeria infection
- Adoptive transfer
- Bone marrow chimeras
Accomplishments
- Validation of 15+ targets including efficient Go/No Go decisions
- 1 program receiving term sheets, 2 licensed for further development
- 7 patents filed and 4 INDs cleared in oncology and inflammation
- Authored 18 publications, including studies in Nature, Science and Blood
- Presented at Keystone Symposia and SITC, advancing thought leadership in immunology
Keyresearchpublications
- Sinclair A, Rosner D, et al., Agonistic IgM Antibodies Targeting Immunostimulatory TNFRSF Members GITR and OX40 Enhance Immune Responses beyond that of IgGs., SITC, 2018
- Lim E, Cugliandolo F, Rosner D, et al., Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors., JCI Insight, 2018
- Ali K, Soond DR, et al., Inactivation of PI(3)K p110δ breaks regulatory T cell-mediated immune tolerance to cancer., Nature, 2014, 510, 7505, 407-11
- Soond DR, et al., Does the PI3K pathway promote or antagonize regulatory T cell development and function?, Frontiers Immunol., 2012, 3, 244
- Soond DR, et al., Pten loss converts effector CD4 T cells into super-helpers but does not lead to autoimmunity or lymphoma., JI, 2012, 188, 12, 5935-43
- Soond DR, et al., PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans., Blood, 2010, 115, 11, 2203-13
Publishedpatents
- Wang B., Rosner DR, Baliga R, Keyt BA., Multimeric ox40 binding molecules and uses thereof., US20220169751A1, 2022
- Wang B., Rosner DR, Baliga R, Keyt BA., Multimeric cd40 binding molecules and uses thereof., US20220106399A1, 2022
- Sun D, Gordon CA, Chai Y, Bonacorsi MZ, Williams SAF, Rosner DR, Shchors K., Antibodies and blocking the interaction of Vista and its binding partner., EP4021942A1, 2022
- Sun D, Tunduguru R, Rosner DR, Shchors K, Rasool S., Anti-gal3 antibodies and methods of use for insulin resistance, US20220411514A1, 2022
- Sun D, Rasool S, Tunduguru R, Bhatia D, Mali VR, Patel MJ, Leong YA, Rosner DR, Shchors K, Hong K., Methods of preventing protein aggregation., WO2023288252A1, 2023
- Srinivisan K, Rosner D, Tassi I, Kuhn J, Ibrahim A, Granger K, Gulbranson D, Marquez M., Anti-ms4a4a antibodies with amyloid-beta therapies., WO2024086796A1, 2024
Timeline
Staff Scientist
Alector
01.2023 - Current
Senior Scientist
True Binding
01.2020 - 01.2021
Scientist II
IGM Biosciences
01.2016 - 01.2020
Postdoctoral Fellow
University of Birmingham
01.2012 - 01.2016
Postdoctoral Fellow
University of Cambridge
01.2009 - 01.2012
M.Sc. - Immunology
University of Colorado
B.A. - Biology
University of Pennsylvania
Ph.D. - Immunology
University of Cambridge